<DOC>
	<DOCNO>NCT01013064</DOCNO>
	<brief_summary>Study design : - Randomized , double-blind , placebo-controlled , sequential dose escalation - Six ascend dose cohort plan Primary Objective : - To evaluate safety profile single escalate intravenous dose level HM10760A</brief_summary>
	<brief_title>A Study HM10760A ( Long-acting Erythropoietin ( EPO ) ) Healthy Korean Subjects</brief_title>
	<detailed_description>Secondary objective : - To evaluate dose response relationship single IV dose HM10760A pharmacodynamic parameter include hemoglobin , reticulocyte count , reticulocyte hemoglobin content - To evaluate pharmacokinetic profile single IV dose level HM10760A - To determine pharmacologically active dose ( PAD ) HM10760A - To assess immunogenicity single IV dose HM10760A</detailed_description>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Age 20 55 year Able willing provide write informed consent Hemoglobin &lt; 16 g/dL Prior exposure EPO , darbepoetin , EPO support proteins hypersensitivity EPO , darbepoetin , E.coli derive protein Hemoglobinopathy SBP &gt; 140 mmHg &lt; 90 mmHg DBP &gt; 95 mmHg Chronic , uncontrolled , symptomatic inflammatory disease Malignancy ( except nonmelanoma skin cancer )</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Erythropoietin</keyword>
	<keyword>Long act</keyword>
	<keyword>EPO</keyword>
</DOC>